Pancreatic Cell News 7.23 June 14, 2016 | |
| |
TOP STORYInvestigators demonstrated that low KMT2C and KMT2D expression in biopsies defines better outcome groups, with median survivals of 15.9 versus 9.2 months, and 19.9 versus 11.8 months respectively. [Cancer Res] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISIn a classical genetic test for cooperative functional interactions, the authors derived mice with combined Pdx1 and Oc1 heterozygosity. Endocrine development in double-heterozygous pancreata was normal at embryonic day (E)13.5, but defects in specification and differentiation were apparent at E15.5, the height of the second wave of differentiation. [Cell Rep] Full Article | Graphical Abstract To investigate the effects of age on β cell metabolism, researchers established a novel assay to directly image islet metabolism using NAD(P)H fluorescence lifetime imaging. [Diabetes] Abstract It has been recently proposed that exposure to polychlorinated biphenyls (PCBs) is a risk factor to type 2 diabetes mellitus. Researchers investigated this hypothesis using long-term in vivo PCB126 exposure to rats addressing metabolic, cellular and proteomic parameters. [Sci Rep] Full Article Scientists previously reported that SEC23B-deficient mice die perinatally, exhibiting massive pancreatic degeneration and that mice with hematopoietic SEC23B deficiency do not exhibit congenital dyserythropoietic anemia type II. They now show that SEC23B deficiency restricted to the pancreas is sufficient to explain the lethality observed in mice with global SEC23B-deficiency. [Sci Rep] Full Article PANCREATIC CANCERScientists evaluated the methylation status of mucin 1 (MUC1) and MUC4 promoter regions in pancreatic tissue samples from 169 patients with various pancreatic lesions by the methylation specific electrophoresis method. [Oncotarget] Full Article Researchers analyzed 11 pancreatic ‘oncocytic subtype’ of intraductal papillary mucinous neoplasms. Nine pancreatic ‘oncocytic subtype’ of intraductal papillary mucinous neoplasms uniformly exhibited typical entity-defining morphology of arborizing papillae lined by layers of cells with oncocytic cytoplasm, prominent, nucleoli, and intraepithelial lumina. [Mod Pathol] Abstract Investigators described that depletion of RUNX2 enhances gemcitabine (GEM) sensitivity of p53-deficient pancreatic cancer AsPC-1 cells through the activation of TAp63-mediated cell death pathway. These findings raised a question whether RUNX2 silencing could also improve GEM efficacy on pancreatic cancer cells bearing p53 mutation. In the present study, they have extended their study to p53-mutated pancreatic cancer MiaPaCa-2 cells. [Oncogenesis] Full Article Scientists analyzed the heterogeneous vascular density of human pancreatic ductal adenocarcinoma along with its prognostic correlation. [Pancreatology] Full Article | |
| |
REVIEWSTherapeutic Advances in Localized Pancreatic Cancer Clinical and preclinical data support the understanding that pancreatic cancer (PC) metastases occur early in the pathogenesis of this disease, even before the primary tumor can be detected. This has important implications for the clinical management of patients with localized PC, as surgery alone is unlikely to be curative for most patients. [JAMA Surg] Full Article Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
| |
SCIENCE NEWSInnovative Approaches to Treating Type 1 Diabetes Addressed in Beta-Cell Replacement Presentations Transplanting islet cells from pigs into humans and developing “universal donor” stem cell lines are two innovative approaches being explored for replacing deteriorating beta cells in people with type 1 diabetes, investigators explained during a news briefing and symposium. [Press release from the American Diabetes Association discussing research presented at the American Diabetes Association’s 76th Scientific Sessions, New Orleans] Press Release Janssen Pharmaceuticals, Inc. announced real-world and clinical findings showing that people with type 2 diabetes treated with INVOKANA® achieved greater blood glucose control and were more likely to stay on therapy than were those treated with dipeptidyl peptidase-4 (DPP-4) inhibitors, a common class of medicines for type 2 diabetes that includes Januvia® (sitagliptin). [Press release from Janssen Pharmaceuticals, Inc. discussing research presented at the American Diabetes Association’s 76th Scientific Sessions, New Orleans] Press Release Sanofi announced the presentation of the results of the pivotal Phase III LixiLan-O and LixiLan-L clinical trials with the investigational titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide in adults with type 2 diabetes. Both studies met their primary endpoints, demonstrating statistically superior reduction of HbA1c with the titratable fixed-ratio combination versus comparators. [Press release from Sanofi discussing research presented at the American Diabetes Association’s 76th Scientific Sessions, New Orleans] Press Release | |
From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
| |
INDUSTRY NEWSA 41-year-old man who was diagnosed with type 1 diabetes at age 11 has become the first patient in Europe to discontinue insulin therapy after receiving a transplant of pancreatic islet cells using an innovative technique developed by the Diabetes Research Institute at the University of Miami. [Diabetes Research Institute Foundation] Press Release MabVax Therapeutics Holdings, Inc. announced the initiation of a second investigational Phase I site for MVT-5873 (HuMab-5B1) with Sarah Cannon Research Institute through its network of research sites. The product is for patients with locally advanced or metastatic adenocarcinoma of the pancreas or other CA19-9 positive malignancies. [MabVax Therapeutics Holdings, Inc.] Press Release
| |
EVENTSNEW International Conference on Stem Cell Engineering 2016 Visit our events page to see a complete list of events in the pancreatic cell community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Fellow – Pancreatic Cancer Metabolism (Thomas Jefferson University) NEW Postdoctoral Fellows – Various Positions (Oregon Health & Science University) NEW Senior Scientific Assistant – Pancreatic Ductal Adenocarcinoma (University of Cambridge) Postdoctoral Fellow – Cell Processes in Pancreatic Cells (University of Copenhagen) Postdoctoral Researcher (Katholieke Universiteit Leuven) Postdoctoral Fellow – Quantitative Hepato-Pancreatic MR Imaging (Inserm) Associate Senior Lecturer – Medical Cell Biology or Physiology (Uppsala University) Postdoctoral Fellow(s) – Pancreatic Islet Biology (Vanderbilt University Medical Center) Postdoctoral Fellow – Pancreas Cancer (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Pancreatic Cell News Volume 7.23 | Jun 14 2016